Clinical Trial

Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients

Study acronym: AR-MHD
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.
Trial Details
NCT Number NCT07412548
Lead Sponsor Universitas Muhammadiyah Surakarta
Conditions Chronic Kidney Disease Stage V, End-Stage Renal Disease, Hemodialysis
Enrollment 76 participants
Start Date 2026-03-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-17